Loading...
Neonc Technologies Holdings, Inc.
NTHI•NASDAQ
HealthcareBiotechnology
$7.42
$-0.07(-0.93%)
Neonc Technologies Holdings, Inc. (NTHI) Stock Overview
Explore Neonc Technologies Holdings, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for NTHIStats details for NTHI are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for NTHIAnalyst Recommendations details for NTHI are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
CEO
Dr. Thomas C. Chen M.D., Ph.D.
Employees
8
Headquarters
8335 Sunset Boulevard, Los Angeles, CA
Founded
2025